Alan K. Burnett - Concepedia

Author

Alan K. Burnett

Cardiff University

Also Known As

A K Burnett, A. Burnett, A. K. Burnett, Alan K. Burnett, Lorna Pearn

Publications

4.6K

Citations

H-Index

Concepts

All Affiliations

Cardiff University University College London The Royal Free Hospital University of Birmingham Cancer Research UK Clinical Trials Unit

About

Alan K. Burnett is an author at Cardiff University specializing in medicine, cancer research, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	2.1K
2	Cell Biology	6	6	1.7K
3	Health Sciences	4	4	382
4	Immunology	4	4	275
5	Pathology	3	3	220

Alan K. Burnett

Publications

4.4K

Citations

H-Index

Page 1

	Year	Citations
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia Mark A. Dawson, Rab K. Prinjha, Antje Dittmann, Nature Hematological MalignancyChromatinBet RecruitmentMixed-phenotype Acute LeukemiaMalignant Blood Disorder	2011	1.5K
Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial Anthony H. Goldstone, Alan K. Burnett, Keith Wheatley, Blood	2001	436
FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia Adam J. Mead, David C. Linch, Robert K. Hills, Blood	2007	320
The prognostic significance of IDH2 mutations in AML depends on the location of the mutation Claire L. Green, C. M. Evans, Lu Zhao, Blood	2011	265
Overproduction of NOX-derived ROS in AML promotes proliferation and is associated with defective oxidative stress signaling Paul S. Hole, Joanna Zabkiewicz, Chinmay Munje, Blood	2013	224
No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials Rosemary E. Gale, Robert K. Hills, Panagiotis Kottaridis, Blood	2005	217
CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia Steven Coles, Eddie C. Y. Wang, Stephen Man, Leukemia Hematological MalignancyTumor BiologyCancer ImmunosurveillanceMixed-phenotype Acute LeukemiaCd200 Expression	2011	172
Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center Roland B. Walter, Megan Othus, Alan K. Burnett, Leukemia Drug Resistance AnalysisHealth SciencesMedicineResistance PredictionPathology	2014	170
The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial Alan K. Burnett, Donald Milligan, Anthony P. Goldstone, British Journal of Haematology Mixed-phenotype Acute LeukemiaPharmacotherapyMyeloid NeoplasiaHematological MalignancyThrombosis	2009	140
Ras-induced reactive oxygen species promote growth factor–independent proliferation in human CD34+ hematopoietic progenitor cells Paul S. Hole, Lorna Pearn, Amanda J. Tonks, Blood	2009	131

Page 1